Asembia AXS25: Cell and Gene Therapies Enter New Phase of Growth in Specialty Pharmacy

Elizabeth Chen Elected 2027 ASCB President

Elizabeth Chen of the University of Texas Southwestern Medical Center has been elected by ASCB members to serve as President of the American Society for Cell Biology (ASCB) in 2027. She will first serve as President-Elect on the ASCB Executive Committee beginning in 2026. Also elected was Andrew Ewald of the Johns Hopkins University School of Medicine, who will begin his term as ASCB Secretary in 2026. New Council Members for 2026ASCB members a…

NBC 2025: Inside CheckImmune’s playbook for cell-specific drug insights

At next week’s National Biotechnology Conference, Berlin-based clinical research firm CheckImmune GmbH will showcase how layering single-cell multi-omics provides insights into drug action and immune responses that bulk readouts (averaged measurements from a large population of cells) often miss. In rapid-fire talks on May 6, the Berlin startup will show how single-cell multiomics and spatial… The post NBC 2025 Preview: Inside CheckImmune’s play…

Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns

Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.

Asembia AXS25: Cell and Gene Therapies Enter New Phase of Growth in Specialty Pharmacy

As the cell and gene therapy pipeline expands, experts at Asembia’s AXS25 Summit emphasized the need for error-proof logistics, value-based access strategies, and coordinated reimbursement models.

Overcoming Barriers to Access in Cell and Gene Therapy | Asembia’s AXS25 Summit

Joe DePinto from McKesson discussed the challenges facing cell and gene therapies, particularly around reimbursement, and highlighted successful strategies to speed up access. He also shared optimism for the future, with many products already achieving blockbuster status and more expected by 2030.